Carvedilol Phosphate Patent Expiration
Carvedilol Phosphate is Used for managing congestive heart failure and hypertension to reduce mortality. It was first introduced by Waylis Therapeutics Llc
Carvedilol Phosphate Patents
Given below is the list of patents protecting Carvedilol Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Coreg Cr |
US8101209 (Pediatric) | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | Mar 11, 2026 | Waylis Therap |
| Coreg Cr | US8101209 | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | Sep 11, 2025 | Waylis Therap |
| Coreg Cr |
US7268156 (Pediatric) | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Dec 27, 2023
(Expired) | Waylis Therap |
| Coreg Cr | US7268156 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Jun 27, 2023
(Expired) | Waylis Therap |
| Coreg Cr |
US6022562 (Pediatric) | Medicinal and/or nutritional microcapsules for oral administration |
Apr 17, 2016
(Expired) | Waylis Therap |
| Coreg Cr |
USRE40000 (Pediatric) | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec 07, 2015
(Expired) | Waylis Therap |
| Coreg Cr | US6022562 | Medicinal and/or nutritional microcapsules for oral administration |
Oct 17, 2015
(Expired) | Waylis Therap |
| Coreg Cr | USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun 07, 2015
(Expired) | Waylis Therap |
Carvedilol Phosphate's Family Patents
Explore Our Curated Drug Screens
Carvedilol Phosphate Generic API Manufacturers
Several generic applications have been filed for Carvedilol Phosphate. The first generic version for Carvedilol Phosphate was by Sun Pharmaceutical Industries Inc and was approved on Oct 25, 2017. And the latest generic version is by Impax Laboratories Inc and was approved on May 7, 2018.
Given below is the list of companies who have filed for Carvedilol Phosphate generic, along with the locations of their manufacturing plants worldwide.
1. IMPAX LABS INC
Impax Laboratories Inc has filed for 4 different strengths of generic version for Carvedilol Phosphate. Given below are the details of the strengths of this generic introduced by Impax Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule, extended release | Prescription | ORAL | AB | May 7, 2018 |
| 20MG | capsule, extended release | Prescription | ORAL | AB | May 7, 2018 |
| 40MG | capsule, extended release | Prescription | ORAL | AB | May 7, 2018 |
| 80MG | capsule, extended release | Prescription | ORAL | AB | May 7, 2018 |
2. SUN PHARM INDUSTRIES
Sun Pharmaceutical Industries Inc has filed for 4 different strengths of generic version for Carvedilol Phosphate. Given below are the details of the strengths of this generic introduced by Sun Pharm Industries.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule, extended release | Prescription | ORAL | AB | Oct 25, 2017 |
| 20MG | capsule, extended release | Prescription | ORAL | AB | Oct 25, 2017 |
| 40MG
(reference standard) | capsule, extended release | Prescription | ORAL | AB | Oct 25, 2017 |
| 80MG | capsule, extended release | Prescription | ORAL | AB | Oct 25, 2017 |